At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 18 enrolled
Drug / intervention
Human Papillomavirus 9-valent Vaccine, Recombinantbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Immune Memory Responses to Human Papillomavirus (HPV) Vaccination Following 2 Verses 3 Doses of Quadrivalent HPV Vaccine
In Brief
A Phase 4 clinical trial evaluating Human Papillomavirus 9-valent Vaccine, Recombinant for Human Papillomavirus. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The overall aim of this study is to further understand the memory response to HPV vaccination in subjects who have received 2 versus 3 doses of quadrivalent HPV vaccine. Although memory responses can be detected shortly after immunization, the best approach to measure the long-lasting anamnestic response is to challenge with a booster dose years (\> 5) after the original exposure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Papillomavirus
CountriesCanada
CollaboratorsMerck Canada Inc.
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartSep 2017
Primary CompletionMay 2019
TodayJul 2026
First PostedNov 18, 2016
Enrollment StartSep 11, 2017
Primary CompletionMay 15, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.6 years ago
Interventions
Human Papillomavirus 9-valent Vaccine, Recombinantbiological
All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.